admin, Author at EnnoDC

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

9th January, 2023 I Paris LinKinVax, a clinical-stage biotechnology company is announcing capital funding for a total of €7,3 M from…

admin In Press Releases

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

10th February, 2022 I Paris LinKinVax, a clinical-stage biotechnology company is announcing completion of a €4.350 million seed capital funding round.…

admin In Press Releases

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

3rd February, 2022 I Paris LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with…

admin In Press Releases

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

26 May 2021 I Paris The funding results from the PSPC-COVID call for projects operated by Bpifrance on behalf of…

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

admin

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

EnnoDC I France
PariSanté Campus
10, rue d’Oradour-sur-Glane
75015 Paris
France

EnnoDC I US
255 Main Street, STE 200
Cambridge, MA 02142-1029
United States

Contact

Terms and Conditions of Use

Legal Information

Privacy Policy

Cookie Policy

Manage consent

© EnnoDC 2024

admin

EnnoDC I France PariSanté Campus 10, rue d’Oradour-sur-Glane 75015 Paris France

EnnoDC I US 255 Main Street, STE 200 Cambridge, MA 02142-1029 United States

© EnnoDC 2024

EnnoDC I France
PariSanté Campus
10, rue d’Oradour-sur-Glane
75015 Paris
France

EnnoDC I US
255 Main Street, STE 200
Cambridge, MA 02142-1029
United States